Consun Pharmaceutical Group Limited disclosed on 11 September 2026 that it repurchased 406,000 ordinary shares on the Hong Kong Stock Exchange one day earlier under its existing buy-back mandate. The shares were acquired at prices ranging from HKD 12.89 to HKD 13.06, with a volume-weighted average cost of HKD 12.98, resulting in a total cash outlay of approximately HKD 5.27 million.

Following the transaction, issued shares (excluding treasury shares) declined 0.0484 % to 838.34 million, while the number of treasury shares increased to 3.21 million. The company’s total issued share count remains unchanged at 841.55 million.

The share buy-back forms part of a mandate approved on 26 May 2026, which authorises the company to repurchase up to 84.12 million shares. Including the latest purchase, Consun Pharma has bought back 2.87 million shares under this mandate, representing 3.41 % of the issued share base on the mandate date. A 30-day moratorium on new share issues or sales of treasury shares applies until 11 October 2026.

Consun Pharma confirmed that the repurchase complied with all relevant listing rules and regulatory requirements.